Skip to main content
OpenTrials
Completed

NCT Number: NCT05465824

Risk Stratification of Patients With Suspected COVID-19 Presenting to the ED

Descriptive study of patients with suspected COVID-19 upon ED arrival of European hospitals between March 09 and April 08 2020.

Justification:

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tours University Hospital

Tours, 37044, France

About this study

Descriptive study of patients with suspected COVID-19 upon ED arrival of European hospitals between March 09 and April 08 2020.

Justification:

Over the past 3 months, the world has faced a novel infection disease outbreak, due to a novel coronavirus, the severe acute respiratory syndrome coronavirus (SARS-CoV2), with a massive impact on healthcare resource.

In Europe, numbers of confirmed cases continue to rise. Europe is currently one of the regions with the highest number of Covid-19 cases and deaths due to this emergent diseases.

Most COVID-19 infected patients present with mild to moderate acute respiratory symptoms, including cough, fever, dyspnea and pneumonia. About 20% will present with severe or critical manifestations of the disease, including pneumonia, respiratory failure and acute respiratory distress syndrome (ARDS).

Anticipating the needs for hospitalization in ward and/or intensive care is crucial.

Emergency departments are at the front line for triaging patients with suspected Covid-19 and referring them to the appropriate level of care.

In Europe, the number of ED patients with suspected Covid-19 is variable; rate of hospitalization from ED reaches 40% for this population.

Risk stratification and management decisions of patients presenting to the ED with suspected COVID-19 is a challenge for emergency physicians.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients (>= 18 years old) attending the ED with a clinical suspicion of COVID-19 based on the presence of the following criteria

  • Fever >= 38 °C
  • respiratory symptoms (dyspnea, cough, expectorations)
  • any other symptoms suggestive of COVID-19 including digestive signs (diarrhea, anosmia…)

Exclusion criteria

  • No insurance
  • patients less than 18 years

Treatment and study plan

Primary outcomes

  1. Mortality

    Time frame: through study completion, an average of 30 days

    Mortality during hospital management

Sponsors and collaborators

Lead sponsor

University Hospital, Tours

Other

Registry information

Acronym: EuroCOV

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Jul 20, 2022
Registry last updated
Sep 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.